Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis
on behalf of the Foch COVID-19 Study Group, Mathilde Roumier, Romain Paule, Alexandre Vallée, Julien Rohmer, Marie Ballester, Anne‐Laure Brun, Charles Cerf, Marie-Laure Chabi, Thierry Chinet, Marie-Alice Colombier, Éric Farfour, Erwan Fourn, Guillaume Géri, D. Khau, Ibrahim Marroun, Matthieu Ponsoye, A. Roux, Hélène Salvator, Y. Schoindre, Anne-Gaëlle Si Larbi, Colas Tchérakian, Marc Vasse, Anne Verrat, Benjamin Zuber, Louis‐Jean Couderc, Jean‐Emmanuel Kahn, Matthieu Groh, Félix Ackermann
Topics & Concepts
Coronavirus disease 2019 (COVID-19)TocilizumabPneumoniaMedical microbiologyMedicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Propensity score matchingBetacoronavirusIntensive care medicineInternal medicineVirologyInfectious disease (medical specialty)OutbreakRheumatoid arthritisDiseaseCOVID-19 Clinical Research StudiesRespiratory Support and MechanismsLong-Term Effects of COVID-19